Genmab As Stock Price on December 12, 2024
| GMAB Stock | USD 21.55 0.28 1.28% |
Below is the normalized historical share price chart for Genmab AS extending back to June 01, 2009. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Genmab AS stands at 21.55, as last reported on the 12th of December 2024, with the highest price reaching 21.78 and the lowest price hitting 21.50 during the day.
If you're considering investing in Genmab Stock, it is important to understand the factors that can impact its price. Genmab AS holds Efficiency (Sharpe) Ratio of -0.22, which attests that the entity had a -0.22% return per unit of risk over the last 3 months. Genmab AS exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Genmab AS's Risk Adjusted Performance of (0.16), standard deviation of 1.54, and Market Risk Adjusted Performance of (2.00) to validate the risk estimate we provide.
At present, Genmab AS's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Liabilities And Stockholders Equity is expected to grow to about 37.1 B, whereas Common Stock Total Equity is forecasted to decline to about 52.4 M. . At present, Genmab AS's Price Book Value Ratio is projected to slightly decrease based on the last few years of reporting. The current year's Price To Operating Cash Flows Ratio is expected to grow to 28.58, whereas Price To Sales Ratio is forecasted to decline to 8.12. Genmab Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 1st of June 2009 | 200 Day MA 26.4995 | 50 Day MA 22.3746 | Beta 0.859 |
Genmab |
Sharpe Ratio = -0.2213
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GMAB |
Estimated Market Risk
| 1.53 actual daily | 13 87% of assets are more volatile |
Expected Return
| -0.34 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.22 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Genmab AS is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genmab AS by adding Genmab AS to a well-diversified portfolio.
Price Book 3.037 | Enterprise Value Ebitda 11.8445 | Price Sales 0.7051 | Shares Float 62.8 M | Wall Street Target Price 36.5556 |
Genmab AS Main Headline on 11th of December 2024
Genmab to Hold 2024 RD Update and ASH Data Review Meeting by finance.yahoo.com
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark December 11, 2024 Genmab AS will hold its 2024 RD Update and ASH Data Review Meeting today, December 11, 2024 at 1100 AM Eastern Time . The event will take place virtually in English and can be attended via live webcast. To register for the webcast, click httpsgenmab-post-ash-2024.open-exchange.net. An archive of the webcast will be avai
Genmab AS Valuation on December 12, 2024
It is possible to determine the worth of Genmab AS on a given historical date. On December 12, 2024 Genmab was worth 21.75 at the beginning of the trading date compared to the closed value of 21.55. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Genmab AS stock. Still, in general, we apply an absolute valuation method to find Genmab AS's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Genmab AS where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Genmab AS's related companies.
| Open | High | Low | Close | Volume | |
| 22.17 | 22.19 | 21.81 | 21.83 | 985,509 | |
12/11/2024 | 21.75 | 21.78 | 21.50 | 21.55 | 636,995 |
| Backtest Genmab AS | | | Genmab AS History | | | Genmab AS Valuation | Previous |
Genmab AS Trading Date Momentum on December 12, 2024
| On December 11 2024 Genmab AS was traded for 21.55 at the closing time. The top price for the day was 21.78 and the lowest listed price was 21.50 . The trading volume for the day was 637 K. The trading history from December 11, 2024 did not cause price change. The overall trading delta against the current closing price is 0.93% . |
Genmab AS Fundamentals Correlations and Trends
By evaluating Genmab AS's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Genmab AS's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Genmab financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Genmab AS Stock history
Genmab AS investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Genmab is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Genmab AS will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Genmab AS stock prices may prove useful in developing a viable investing in Genmab AS
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 65.9 M | 62.6 M | |
| Net Income Applicable To Common Shares | 6.4 B | 6.7 B |
Genmab AS Quarterly Net Working Capital |
|
Genmab AS Stock Technical Analysis
Genmab AS technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Genmab AS Period Price Range
Low | December 12, 2024
| High |
0.00 | 0.00 |
Genmab AS cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Genmab AS December 12, 2024 Market Strength
Market strength indicators help investors to evaluate how Genmab AS stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Genmab AS shares will generate the highest return on investment. By undertsting and applying Genmab AS stock market strength indicators, traders can identify Genmab AS entry and exit signals to maximize returns
Genmab AS Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Genmab AS's price direction in advance. Along with the technical and fundamental analysis of Genmab Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Genmab to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.16) | |||
| Jensen Alpha | (0.39) | |||
| Total Risk Alpha | (0.61) | |||
| Treynor Ratio | (2.01) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |